Last updated 3 days ago
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
915 patients around the world
Available in Brazil, Chile, United States
Regeneron Pharmaceuticals
2Research sites
915Patients around the world
This study is for people with
Multiple myeloma
Requirements for the patient
From 18 Years
All Gender
Medical requirements
- Participant with RRMM who received at least 1 but not more than 3 prior lines of therapy, which must have included treatment with lenalidomide and either a Protease Inhibitor (PI) or anti-CD38 monoclonal antibody.Eastern Cooperative Oncology Group (ECOG) performance status score ≤2.Confirmed progressive disease according to IMWG criteria during or after the most recent line of therapy.
- Prior treatment with a T cell-based immunotherapy targeting BCMA, including BCMA-directed bispecific antibodies, Bispecific T-cell Engagers (BiTEs), and Chimeric Antigen Receptor (CAR) T cells. Antibody-drug conjugates targeting BCMA (eg, belantamab mafodotin) are not excluded.Diagnosis of plasma cell leukemia, symptomatic amyloidosis (including myeloma-associated amyloidosis), Waldenström macroglobulinemia (lymphoplasmacytic lymphoma), or POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes).Known Central Nervous System (CNS) involvement of myeloma including meningeal involvement.History of neurodegenerative condition, Progressive Multifocal Leukoencephalopathy (PML), or CNS movement disorder.
Sites
Centro Gaucho Integrado de Oncologia, Hematologia, Ensino e Pesquisa - Mãe de Deus Hospital
Recruiting
Centro de Oncología de Precisión - Santiago de Chile
Recruiting
StudyLINKER-MM5
SponsorRegeneron Pharmaceuticals
Study typeInterventional
Conditions
Multiple myeloma
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT07222761
